Medindia

X

FDA Approves Remodulin for Pulmonary Hypertension

by Medindia Content Team on  September 9, 2002 at 5:24 PM Drug News   - G J E 4
FDA Approves Remodulin for Pulmonary Hypertension
According to a notice distributed by the agency, the US Food and Drug Administration (FDA) has approved United Therapeutics Corp.'s pulmonary arterial hypertension therapy Remodulin (treprostinil sodium). A spokesperson for the FDA told Reuters Health that the approved indication covers NYHA class II-IV pulmonary arterial hypertension. The FDA approved the drug under subpart H, which allows for marketing clearance based on an effect on a surrogate endpoint, provided well-controlled postmarketing studies are conducted.
Advertisement

United Therapeutics received an approvable letter for Remodulin earlier this year after the FDA's Cardiovascular and Renal Drugs Advisory Committee voted 6-3 in August 2001 to recommend approval.

Advertisement
Remodulin is a synthetic formulation of prostacyclin designed for subcutaneous infusion using a small device developed by Medtronic MiniMed Inc. of Minneapolis, Minnesota.

The drug will compete with GlaxoSmithKline's Flolan (epoprostenol), a synthetic form of prostacyclin delivered via an external pump and an intravenous catheter. United Therapeutics has claimed that Remodulin's delivery system helps reduce the risk of sepsis associated with the delivery of Flolan.

Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All